BioCentury
ARTICLE | Clinical News

Autologous CD34+ cells: Phase I/II data

August 5, 2013 7:00 AM UTC

The open-label, Italian Phase I/II TIGET-WAS trial showed that all 3 evaluable patients who received IV infusions of autologous CD34+ cells transfected with a lentiviral vector encoding functional Wis...